Pipeline Therapeutics to Present at Stifel 2020 Virtual Healthcare Conference

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, November 12, 2020
Information
Tags: 
Professional services, Health, Finance, Clinical trials, Pharmaceutical, Biotechnology, Biology, Neurology, Remyelination, Neuroregeneration, Axon, Life sciences
Geotags: 
United States, California
⚠generated by AI ↴
Summary
Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability.
  • The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.


Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m. ET / 11:00 a.m. PT.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

Copyright: 
Copyright Business Wire 2020